gms | German Medical Science

77. Jahresversammlung der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e. V.

Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e. V.

24.05. - 28.05.2006, Mannheim

Promotermethylation of three new tumor suppressor genes in HNSCC and their precursor lesions

Meeting Abstract

German Society of Otorhinolaryngology, Head and Neck Surgery. 77th Annual Meeting of the German Society of Otorhinolaryngology, Head and Neck Surgery. Mannheim, 24.-28.05.2006. Düsseldorf, Köln: German Medical Science; 2006. Doc06hno077

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/hno2006/06hno077.shtml

Veröffentlicht: 7. September 2006

© 2006 Weber et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Aim: Promoter methylation is an epigenetic mechanism resulting in loss of protein expression despite intakt gene. Recent studies demonstrate an inactivation of three new tumor suppressor genes (Semaphorin 3B (SEMA3B), BLU and RASSF1, located on 3p21, due to methylation of their promoter. We examined the role of methylation of the three abovementioned genes in the carcinogenesis of squamous cell carcinomas of the head and neck (HNSCC).

Material and methods: Promoter methylation of SEMA3B, BLU, RASSF1 was examined by MSP PCR in 95 HNSCC, 21 lowgrade and 16 highgrade intraepithelial neoplasias. Semiquantitative m- RNA expression was examined by RT- PCR.

Results: SEMA3B promoter methylation was present in 12/95 HNSCC and in none of the neoplasias. BLU was methylated in 29% of the carcinomas and in 18% and 9% of highgrade and lowgrade neoplasias, respectively. The promoter of RASSF1 was methylated in 19% of the carcinomas, 12% of high grade and 5% of low grade intraepithelial neoplasias. M-RNA expression of SEMA3B, BLU and RASSF1 was reduced in samples with promoter methylation.

Conclusion: Our results demomstrate that methylation of SEMA3B, BLU and RASSF1 does not play a major role in carcinogenesis of HNSCC. However in some carcinomas it occurs as an early event even in low grade neoplasias.